Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J)

Circulation Journal

Volumn 77, Issue 9, 2013, Pages 2341-2348

  Ogawa, Hisao ^a   Goto, Shinya ^b   Matsuzaki, Masunori ^c   Hiro, Shintaro ^d   Shima, Daisuke ^e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Department of Medicine and Clinical Statistics ^*  (Japan)

^e Pfzer Japan Inc   (Japan)

Author keywords

Acute coronary syndrome; Apixaban; Factor Xa inhibitor; Japanese patients; Oral anticoagulant

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; PLACEBO; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; LIVER FUNCTION; MALE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE CORONARY SYNDROME; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; JAPAN; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; PYRIDONES;

EID: 84882774738     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0209     Document Type: Article

References (30)

1. Nishigaki K, Yamazaki T, Fukunishi M, Tanihata S, Fujiwara H. Assessment of acute myocardial infarction in Japan by the Japanese Coronary Intervention Study (JCIS) Group. Circ J 2004; 68: 515-519.
2. Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H. One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and a trial fibrillation: Results from the Japan Thrombosis Registry for A trial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). Circ J 2011; 75: 2598-2604.
3. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
4. Barbash IM, Freimark D, Gottlieb S, Hod H, Hasin Y, Battler A, et al. Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre-hospital administration. Cardiology 2002; 98: 141-147.
5. Freimark D, Matetzky S, Leor J, Boyko V, Barbash IM, Behar S, et al. Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. Am J Cardiol 2002; 89: 381-385.
6. O'Connor RE, Brady W, Brooks SC, Diercks D, Egan J, Ghaemmaghami C, et al. Part 10: Acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122: S787-S817.
7. JCS Joint Working Group. Guidelines for management of patients with ST-elevation myocardial infarction. Circ J 2008; 72(Suppl IV): 1347-1442.
8. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
9. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
10. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with a trial fibrillation. Arch Intern Med 2010; 170: 1433-1441.
11. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
12. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-1974.
13. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with a trial fibrillation. J Am Coll Cardiol 2007; 50: 309-315.
14. Hankey GJ, Stevens S, Piccini J, Lokhnygina Y, Mahaffey KW, Halperin JL, et al. Predictors of intracranial hemorrhage among anti coagulated patients with a trial fibrillation: Insights from the Rivar-oxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in A trial Fibrillation (ROCKET AF). Stroke 2012; 43: A152.
15. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multi center, observational study. Stroke 2008; 39: 1740-1745.
16. Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3-car-boxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bio available inhibitor of blood coagulation factor Xa. J Med Chem 2007; 50: 5339-5356.
17. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6: 820-829.
18. Bristol-Myers Squibb, Pfzer EEIG. Eliquis® (apixaban tablets) Summary of product characteristics. EMA. June 20, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_In-formation/human/002148/WC500107728.pdf (accessed September 28, 2011).
19. Mandema JW, Boyd RA, DiCarlo LA. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: A dose-response meta-analysis. Clin Pharmacol Ther 2011; 90: 820-827.
20. Yamahira N, Imai Y, Wastall P, Liao S, Frost C, Fukase H, et al. A placebo-controlled, ascending multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of apixaban in healthy Japanese subjects (A637). Can J Clin Pharmacol 2008; 15: e420-e781. http://www.jptcp.com/pubmed.php?articleId=166 (accessed February 7, 2013).
21. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-2885.
22. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708.
23. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
24. Goto S, Ikeda Y, Chan J, Wilson P, Cheng Yeo T, Liau C, et al. Risk-factor profile, drug usage and cardiovascular events within a year in patients with and a high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asia regions: A sub study of the Reduction of Atherothrombosis for Continued Health (REACH) registry. Heart Asia 2011; 3: 93-98.
25. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133: 670S-707S.
26. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2011; 366: 9-19.
27. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. New oral anticoagulants in a trial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper. J Am Coll Cardiol 2012; 59: 1413-1425.
28. JCS Joint Working Group. Guidelines for secondary prevention of myocardial infarction (JCS 2011): Digest version. Circ J 2013; 77: 231-248.
29. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non valvular a trial fibrillation: The ARISTOTLE-J study. Circ J 2011; 75: 1852-1859.
30. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with a trial fibrillation. N Engl J Med 2011; 365: 981-992.